APA (7th ed.) Citation

M, C., M, C., SW, H., K, R., A, L., JH, S., . . . MR, S. (2026). A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.10.105

Chicago Style (17th ed.) Citation

M, Cecchini, et al. "A Randomized Phase 1 Study of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in Combination with Bevacizumab Versus Trifluridine-tipiracil with Bevacizumab in Patients with Metastatic Colorectal Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 2026. https://doi.org/10.1016/j.annonc.2026.10.105.

MLA (9th ed.) Citation

M, Cecchini, et al. "A Randomized Phase 1 Study of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in Combination with Bevacizumab Versus Trifluridine-tipiracil with Bevacizumab in Patients with Metastatic Colorectal Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2026, https://doi.org/10.1016/j.annonc.2026.10.105.